CG Invites Co., Ltd. (KOSDAQ:083790)

Market Cap	68.67B -55.4%
Revenue (ttm)	29.22B +224.6%
Net Income	-3.23B
EPS	-42.15
Shares Out	76.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,369
Open	855.00
Previous Close	855.00
Day's Range	809.00 - 899.00
52-Week Range	760.00 - 2,015.00
Beta	-0.02
Analysts	Buy
Price Target	24,102.56 (+2,599.06%)
Earnings Date	Aug 13, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 105
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2025, CG Invites's revenue was 27.39 billion, an increase of 277.64% compared to the previous year's 7.25 billion. Losses were -3.52 billion, -93.17% less than in 2024.